SUMMARY Thymus-derived lymphocytes (T lymphocytes) were enumerated in patients with uveal malignant melanoma. Two T-lymphocyte subpopulations were determined, the active rosette forming cells (A-RFC) and the total rosette forming cells (T-RFC). Subjects were divided into the following groups: (a) pretreatment patients, (b) patients treated by enucleation, (c) patients treated by photocoagulation, (d) patients treated by cobalt plaque radiotherapy, (e) patients treated by enucleation who developed clinically detectable metastasis, and (f) normal controls. There were no differences in the numbers of A-RFC or T-RFC in the control population, pretreatment patients, and those treated in the different ways. Statistically significant depressions of A-RFC and T-RFC levels were seen in patients with metastatic lesions, suggesting that they had an impairment of immunocompetence, as measured by T-lymphocyte rosette formation.
Immune surveillance of solid tumours is generally accepted to be a function of the cell-mediated immune system. The ability of malignant cells to escape surveillance has been postulated to be due to a number of mechanisms such as the 'shedding' of tumour antigens or of other tumour products which can cause the suppression of the host's immune system.
I
Cell-mediated immune responses have been demonstrated by in-vitro and in-vivo methods in patients with uveal malignant melanoma.23
In this study active rosette forming cells (A-RFC) and total rosette forming cells (T-RFC) were enumerated as a measure of cell-mediated immunity because they are reported to correlate well with cellmediated immunity.4 A-RFC represent a special subset of T lymphocytes that have a higher affinity for sheep erythrocytes (E) and have a more consistent relationship to active immunity than do T-RFC.5
A-RFC probably represent 'activated' T lympho- 
Results
The numbers of A-RFC and T-RFC enumerated for the pretherapy patients and the controls are presented in Table 1 . Overall no statistical difference was found between the two groups. During the course of the study no significant changes in the number of rosette forming cells were found in the patients treated by enucleation, photocoagulation, or cobalt plaque irradiation (Table 2) . On the other hand those nine patients who developed metastatic melanoma had significantly (p<0O001) decreased levels of A-RFC and T-RFC. Serial enumerations of the two rosette forming cell populations in Fig. 1 showed decreasing levels of A-RFC and T-RFC even before the clinical detection of metastatic disease.
Discussion
The loss of immunocompetance as measured by rosette forming cells in the general circulation has been previously described in other malignancies at the time of diagnosis.' "' In this study we found no statistically significant differences in A-RFC and T-RFC levels at the time of diagnosis in 80 patients with malignant melanoma of the uvea (Table 1) . Recently several authors have suggested that an increased mortality rate following enucleation may be due to several possible mechanisms, including tumour dispersion during surgery, enucleation selectively given to those patients with large or rapidly growing tumours, or immunosuppression following surgery and anaesthetic. "-"4 To assess the immunocompetance of patients after therapy for their uveal malignant melanoma we compared the numbers of A-RFC and T-RFC in patients treated in different ways. We could find no differences in the numbers of A-RFC or T-RFC in the patients treated by enucleation photocoagulation or cobalt plaque irradiation (Table 2 ). Our results suggest that, if indeed these forms of therapy can induce an immunosuppression, it does not appear to be detectable with assays such as A-RFC or T-RFC enumeration.
Metastasis in other cancers has been associated with immunosuppression related to depressed numbers of rosette forming cells.' Our study extends these observations to uveal malignant melanoma. We have detected depressed numbers of A-RFC and T-RFC as much as three months prior to the clinical detection of or death due to metastasis (Table 3 , Fig.  1 ). In addition decreased T cells have been reported in patients with systemic metastases from uveal melanoma by a different rosetting technique. "
From the results of our study we do not believe that there is any diagnostic value in enumerating A-RFC and T-RFC lymphocytes in the initial evaluation of patients with uveal malignant melanoma. A-RFC and 
